Topical Antiperspirant for Hand-Foot Syndrome

University of Wisconsin, Madison14 enrolled

Overview

The objectives of this study are to evaluate the effectiveness of an antiperspirant in preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with the Food and Drug Administration (FDA)-approved doses of capecitabine. The hypothesis is that cytotoxic compounds in sweat will be prevented from being deposited in the skin and causing chronic toxicity.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Palmar-plantar Erythrodysesthesia

Interventions

antiperspirantDRUG

antiperspirant topically once daily to one foot

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Has not previously received a regimen that includes 5-fluorouracil * \> 18 years old * No known allergy or intolerance to Ban Unscented Roll-On Antiperspirant Exclusion Criteria: * \< 18 years of age

Locations (1)

University of Wisconsin

Madison, Wisconsin, United States

Outcomes

Primary Outcomes

reduction in palm and/or sole pain

Time frame: after each of first four cycles of chemotherapy

Secondary Outcomes

evaluation of utility of digital photography in the following palmar-plantar erythrodysesthesia (PPES)

Time frame: after each of first four cycles of chemotherapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.